Boulder, CO – August 20, 2024 – Ambrosia Biosciences Inc. (“Ambrosia” or “the Company”), today announced the successful first closing of its Series A financing. The financing totaled $16 Million and was led by BVF Partners and Boulder Ventures. Ambrosia’s financing will be used to scale up its drug discovery programs and laboratory operations in Boulder, CO.
Read MoreFor Joel Holland, what started as an impulsive decision with his wife to travel the United States in an RV has grown into a business and network that supports over 5,500 small businesses across the country, including a few right in Eagle County.
Read MoreLâle White, CEO of XiFin, wins “CEO of the Year” by San Diego Business Journal for her transformative leadership and significant contributions to the healthcare industry.
Read MoreThis summer, Frasca Food and Wine will celebrate 20 years as one of Colorado's most preeminent restaurants, overseen by wine expert Bobby Stuckey. The establishment, which pairs regional Italian dishes with an 800-bottle wine list, is now one of the state's first restaurants to earn a Michelin star.
Read MoreKendall Clark is the co-founder and CEO of Stardog, a leading enterprise knowledge graph platform with prestigious customers like Morgan Stanley, Raytheon, Bosch, and NASA. He founded the company in 2016 with a vision of making data access more meaningful. Self-taught in coding during his 20s, Kendall is on a mission to help people experience "aha" moments with data more frequently.
Read MoreIRVINE, Calif., and BOULDER, Colo. May 13, 2024 (GLOBE NEWSWIRE) Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing OnKure’s pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), including its lead program OKI-219, which is currently in a Phase 1 clinical trial for the treatment of solid tumors. Upon completion of the transaction, the combined company is expected to operate under the name OnKure Therapeutics, Inc., and trade on the Nasdaq Global Market under the ticker symbol “OKUR”.
Read MoreIt's the end of an era at Cisco Systems.
John Chapman, the well-regarded cable industry vet and DOCSIS pioneer, confirmed that he will be leaving Cisco amid a recent wave of layoffs that will impact about 5% of the company's workforce – or roughly 4,000 jobs.
Chapman currently serves as CTO, broadband, and a fellow at Cisco, covering areas such as PON, fixed wireless access (FWA) and mobile.
He joined the company more than 34 years ago and recalls being interviewed by Cisco founders Leonard Bosack and Sandy Lerner. He came aboard while Cisco was still a private startup with about 20 design engineers and 70 people across the whole company, he recalls.
Read MoreSoftware testing is hard. Even with the right talent in place, it doesn’t always go as planned — particularly when executed at scale. In a 2020 survey from Electric Cloud, 58% of developers blamed software bugs on test infrastructure and process issues — not design defects.
The market for software testing solutions is quite massive, unsurprisingly, with one estimate pegging it at $55.98 billion. There’s plenty of vendors in the space, from startups like Qase, EvaluAgent and Codegen to incumbents like Azure and AWS.
But a new entrant, Antithesis, thinks it can make a splash.
Read More
